Prescription medicine
Solriamfetol Brand names: Sunosi
Solriamfetol (Sunosi) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $31.34 per Sunosi 150 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
- DEA Schedule IV
Check it at the source: the solriamfetol FDA label on DailyMed (effective May 5, 2026, Axsome Therapeutics, Inc.); the NDA 211230 record on Drugs@FDA; every solriamfetol label on DailyMed.
Highlights of the record
FDA label of May 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )].
Forms and strengths
- 75 mg
- 150 mg
Film-coated tablet.
On the market
- Earliest approval on file
- March 20, 2019 Sunosi, Axsome Malta; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 2 first June 17, 2026; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 30, 2042 Sunosi tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $31.34 per tablet Sunosi 150 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,777 through July 30, 2026
What is solriamfetol used for?
From the label: indications and usageSUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )]. Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities. […]
FDA pharmacologic class: Dopamine and Norepinephrine Reuptake Inhibitor.
Source: FDA drug label (SUNOSI), Axsome Therapeutics, Inc., effective May 5, 2026 (SPL set 362f206b-73e7-4009-8c34-5a9df55679ab), via openFDA; the full label on DailyMed
Is there a generic for solriamfetol (Sunosi)?
The FDA approved the first generic solriamfetol on June 17, 2026. 2 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 42 patents for Sunosi tablets: the compound patent runs to November 1, 2038, and the last listed entry to December 30, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2026 first generic approved
- 2042 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for solriamfetol (Sunosi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $31.34 per Sunosi 150 mg tablet, up 6% from $29.49 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Sunosi 150 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Sunosi 150 mg tablet | Brand | $31.34 per tablet | $940.29 | +6% |
| Sunosi 75 mg tablet | Brand | $31.37 per tablet | $941.07 | +6% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for solriamfetol?
The FDA Adverse Event Reporting System holds 3,777 reports that list solriamfetol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 14 are coded as a death and 329 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Solriamfetol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other